Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

The Lancet Gastroenterology & Hepatology - Tập 8 - Trang 1080-1093 - 2023
Stephen A Harrison1,2, Juan P Frias3, Guy Neff4, Gary A Abrams5, K Jean Lucas6, William Sanchez7, Sudhanshu Gogia8, Muhammed Y Sheikh9, Cynthia Behling10, Pierre Bedossa11,12, Lan Shao13, Doreen Chan14, Erica Fong14, Brittany de Temple14, Reshma Shringarpure14, Erik J Tillman14, Timothy Rolph14, Andrew Cheng14, Kitty Yale14
1Department of Hepatology, University of Oxford, Oxford, UK
2Pinnacle Clinical Research, San Antonio, TX, USA
3Velocity Clinical Research, Los Angeles, CA, USA
4Covenant Metabolic Specialists, Sarasota, FL, USA
5Department of Medicine, Prisma Health Upstate, Greenville, SC, USA
6Lucas Research, Morehead, NC, USA
7Floridian Clinical Research, Miami Lakes, FL, USA
8Texas Digestive Disease Institute, Webster, TX, USA
9Fresno Clinical Research Center, Fresno, CA, USA
10Department of Pathology, Sharp Memorial Hospital, San Diego, CA, USA
11Liverpat, Paris, France
12Institute of Cellular Medicine, University of Newcastle, Newcastle, Upon Tyne, UK
13Statistics, Labcorp, Burlington, NC, USA
14Akero Therapeutics, South San Francisco, CA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Gastroenterology & Hepatology

Tập 8

1080-1093

Thông tin tác giả